Literature DB >> 31096231

The Incidence of Childhood Thyrotoxicosis Is Increasing in Both Girls and Boys in Sweden.

Maria Rodanaki1, Maria Lodefalk2,3, Katharina Forssell4, Carl-Göran Arvidsson5, Maria Forssberg4, Jan Åman1.   

Abstract

BACKGROUND: We found an increase in the incidence rate (IR) of childhood thyrotoxicosis (CT) during the 1990s in central Sweden. The optimal treatment method for CT is a subject that is still debated upon.
OBJECTIVES: To investigate whether the increase in IR of CT in Sweden persists and to study the treatment outcome.
METHOD: Children <16 years of age diagnosed with CT during 2000-2009 and living in 1 of 5 counties in central Sweden were identified retrospectively using hospital registers. Data on clinical and biochemical characteristics and outcomes of treatment were collected from medical records. The corresponding data from 1990 to 1999 were pooled with the new data.
RESULTS: In total, 113 children were diagnosed with CT during 1990-2009 in the study area. The overall IR was 2.2/100,000 person-years (95% CI 1.2-2.5/100,000 person-years). The IR was significantly higher during 2000-2009 than during 1990-1999 (2.8/100,000 [2.2-3.6] vs. 1.6/100,000 person-years [1.2-2.2], p = 0.006). The increase was significant for both sexes. Seventy percent of the patients who completed the planned initial treatment with antithyroid drugs (ATDs) and were not lost to follow-up relapsed within 3 years. Boys tended to relapse earlier than girls (6.0 months after drug withdrawal [95% CI 1.9-10.0] vs. 12.0 months [95% CI 6.8-17.3], p = 0.074).
CONCLUSIONS: The IR of CT is increasing in both girls and boys. Relapse rate after withdrawal of ATD treatment is 70%. Boys tend to relapse earlier than girls, and this needs to be further investigated.
© 2019 The Author(s)Published by S. Karger AG, Basel.

Entities:  

Keywords:  Children; Hyperthyroidism; Incidence rate; Relapse; Thyrotoxicosis

Mesh:

Substances:

Year:  2019        PMID: 31096231      PMCID: PMC6690413          DOI: 10.1159/000500265

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  38 in total

Review 1.  Thyroid carcinoma in Graves' disease: A meta-analysis.

Authors:  Joy U L Staniforth; Senarath Erdirimanne; Guy D Eslick
Journal:  Int J Surg       Date:  2015-11-26       Impact factor: 6.071

2.  Increasing prevalence of coeliac disease over time.

Authors:  S Lohi; K Mustalahti; K Kaukinen; K Laurila; P Collin; H Rissanen; O Lohi; E Bravi; M Gasparin; A Reunanen; M Mäki
Journal:  Aliment Pharmacol Ther       Date:  2007-11-01       Impact factor: 8.171

Review 3.  Controversies in the pharmacological treatment of Graves' disease in children.

Authors:  Filippo De Luca; Mariella Valenzise
Journal:  Expert Rev Clin Pharmacol       Date:  2018-11-15       Impact factor: 5.045

4.  Increasing incidence of childhood Graves' disease in Hong Kong: a follow-up study.

Authors:  G W Wong; P S Cheng
Journal:  Clin Endocrinol (Oxf)       Date:  2001-04       Impact factor: 3.478

Review 5.  Approach to the pediatric patient with Graves' disease: when is definitive therapy warranted?

Authors:  Andrew J Bauer
Journal:  J Clin Endocrinol Metab       Date:  2011-03       Impact factor: 5.958

6.  Incidence of hyperthyroidism in Sweden.

Authors:  Mirna Abraham-Nordling; Kristina Byström; Ove Törring; Mikael Lantz; Gertrud Berg; Jan Calissendorff; Helena Filipsson Nyström; Svante Jansson; Gun Jörneskog; F Anders Karlsson; Ernst Nyström; Hans Ohrling; Thomas Orn; Bengt Hallengren; Göran Wallin
Journal:  Eur J Endocrinol       Date:  2011-09-09       Impact factor: 6.664

7.  Long-term outcomes of pediatric Graves' disease.

Authors:  Ganesh Jevalikar; Julieta Solis; Margaret Zacharin
Journal:  J Pediatr Endocrinol Metab       Date:  2014-11       Impact factor: 1.634

Review 8.  Graves' disease in children.

Authors:  Juliane Léger; Isabelle Oliver; Danielle Rodrigue; Anne-Sophie Lambert; Régis Coutant
Journal:  Ann Endocrinol (Paris)       Date:  2018-08-16       Impact factor: 2.478

Review 9.  Incidence and trend of type 1 diabetes and the underlying environmental determinants.

Authors:  Ying Xia; Zhiguo Xie; Gan Huang; Zhiguang Zhou
Journal:  Diabetes Metab Res Rev       Date:  2018-10-11       Impact factor: 4.876

10.  Long-term outcome of thyrotoxicosis in childhood and adolescence in the west of Scotland: the case for long-term antithyroid treatment and the importance of initial counselling.

Authors:  Mariam Kourime; Sheena McGowan; Mabrouka Al Towati; S Faisal Ahmed; Graham Stewart; Scott Williamson; Iain Hunter; Malcolm D C Donaldson
Journal:  Arch Dis Child       Date:  2017-12-21       Impact factor: 3.791

View more
  5 in total

1.  An Estimation of the Incidence of Thyroiditis Among Girls in Primary Care in Spain

Authors:  Elisa Martín-Merino; Aida Moreno-Juste; Belén Castillo Cano; Mar Martín Pérez; Dolores Montero Corominas
Journal:  J Clin Res Pediatr Endocrinol       Date:  2020-12-02

Review 2.  How to use thionamide anti-thyroid drug in the young- what's new?

Authors:  Tim Cheetham
Journal:  Thyroid Res       Date:  2021-07-21

3.  An Intronic HCP5 Variant Is Associated With Age of Onset and Susceptibility to Graves Disease in UK and Polish Cohorts.

Authors:  Laura Claire Lane; Aleksander Kuś; Tomasz Bednarczuk; Artur Bossowski; Jacek Daroszewski; Beata Jurecka-Lubieniecka; Heather Jane Cordell; Simon Henry Schofield Pearce; Timothy Cheetham; Anna Louise Mitchell
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

4.  2022 European Thyroid Association Guideline for the management of pediatric Graves' disease.

Authors:  Christiaan F Mooij; Timothy D Cheetham; Frederik A Verburg; Anja Eckstein; Simon H Pearce; Juliane Léger; A S Paul van Trotsenburg
Journal:  Eur Thyroid J       Date:  2022-01-01

5.  Hyperthyroidism in children and adolescents: Experience in a university hospital in Colombia

Authors:  Judith Sofía García; María Paula Sarmiento; Jesús David Bello; Nora Alejandra Zuluaga; Adriana Carolina Forero; Laura Fernanda Niño
Journal:  Biomedica       Date:  2022-06-01       Impact factor: 1.173

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.